FDA Seems Unlikely To Move Hydrocodone To Stricter Class

Law360, New York (October 31, 2012, 8:18 PM EDT) -- A key U.S. Food and Drug Administration official appeared to be leaning against recommending that hydrocodone-based painkillers be reclassified to a more restrictive drug schedule, according to new documents — a good sign for drugmakers and pharmacists who oppose up-scheduling.

The FDA released the documents last Thursday, ahead of a scheduled meeting looking at whether to change the Controlled Substances Act classification for hydrocodone combination products from Schedule III to the more restrictive Schedule II.

Hydrocodone products, such as Abbott Laboratories' Vicodin, are some of the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.